Your browser doesn't support javascript.
loading
Influenza Vaccine Effectiveness and Waning Effect in Hospitalized Older Adults. Valencia Region, Spain, 2018/2019 Season.
Mira-Iglesias, Ainara; López-Labrador, F Xavier; García-Rubio, Javier; Mengual-Chuliá, Beatriz; Tortajada-Girbés, Miguel; Mollar-Maseres, Joan; Carballido-Fernández, Mario; Schwarz-Chavarri, Germán; Puig-Barberà, Joan; Díez-Domingo, Javier.
Affiliation
  • Mira-Iglesias A; Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain.
  • López-Labrador FX; Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain.
  • García-Rubio J; Consorcio de Investigación Biomédica de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.
  • Mengual-Chuliá B; Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain.
  • Tortajada-Girbés M; Fundación Para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO-Public Health), 46020 Valencia, Spain.
  • Mollar-Maseres J; Hospital Universitario Doctor Peset, 46017 Valencia, Spain.
  • Carballido-Fernández M; Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
  • Schwarz-Chavarri G; Hospital General Universitario de Castellón, 12004 Castellón, Spain.
  • Puig-Barberà J; Departamento Medicina, Universidad CEU Cardenal Herrera, 12006 Castellón, Spain.
  • Díez-Domingo J; Hospital General Universitario de Alicante, 03010 Alicante, Spain.
Article in En | MEDLINE | ID: mdl-33514058
ABSTRACT
Influenza vaccination is annually recommended for specific populations at risk, such as older adults. We estimated the 2018/2019 influenza vaccine effectiveness (IVE) overall, by influenza subtype, type of vaccine, and by time elapsed since vaccination among subjects 65 years old or over in a multicenter prospective study in the Valencia Hospital Surveillance Network for the Study of Influenza and other Respiratory Viruses (VAHNSI, Spain). Information about potential confounders was obtained from clinical registries and/or by interviewing patients and vaccination details were only ascertained by registries. A test-negative design was performed in order to estimate IVE. As a result, IVE was estimated at 46% (95% confidence interval (CI) (16%, 66%)), 41% (95% CI (-34%, 74%)), and 45% (95% CI (7%, 67%)) against overall influenza, A(H1N1)pdm09 and A(H3N2), respectively. An intra-seasonal not relevant waning effect was detected. The IVE for the adjuvanted vaccine in ≥75 years old was 45% (2%, 69%) and for the non-adjuvanted vaccine in 65-74 years old was 59% (-16%, 86%). Thus, our data revealed moderate vaccine effectiveness against influenza A(H3N2) and not significant against A(H1N1)pdm09. Significant protection was conferred by the adjuvanted vaccine to patients ≥75 years old. Moreover, an intra-seasonal not relevant waning effect was detected, and a not significant IVE decreasing trend was observed over time.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / Influenza A Virus, H1N1 Subtype Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Aged / Humans Country/Region as subject: Europa Language: En Journal: Int J Environ Res Public Health Year: 2021 Document type: Article Affiliation country: Spain

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Influenza Vaccines / Influenza, Human / Influenza A Virus, H1N1 Subtype Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Aged / Humans Country/Region as subject: Europa Language: En Journal: Int J Environ Res Public Health Year: 2021 Document type: Article Affiliation country: Spain